208 related articles for article (PubMed ID: 36153599)
1. Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease.
Mishra N; Aden K; Blase JI; Baran N; Bordoni D; Tran F; Conrad C; Avalos D; Jaeckel C; Scherer M; Sørensen SB; Overgaard SH; Schulte B; Nikolaus S; Rey G; Gasparoni G; Lyons PA; Schultze JL; Walter J; Andersen V; ; Dermitzakis ET; Schreiber S; Rosenstiel P
Genome Med; 2022 Sep; 14(1):110. PubMed ID: 36153599
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
[TBL] [Abstract][Full Text] [Related]
3. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
Salvador-Martín S; Raposo-Gutiérrez I; Navas-López VM; Gallego-Fernández C; Moreno-Álvarez A; Solar-Boga A; Muñoz-Codoceo R; Magallares L; Martínez-Ojinaga E; Fobelo MJ; Millán-Jiménez A; Rodriguez-Martinez A; Vayo CA; Sánchez C; Tolin M; Bossacoma F; Pujol-Muncunill G; González de Caldas R; Loverdos I; Blanca-García JA; Segarra O; Eizaguirre FJ; García-Romero R; Merino-Bohórquez V; Sanjurjo-Sáez M; López-Fernández LA
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397546
[TBL] [Abstract][Full Text] [Related]
4. Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment.
Salvador-Martín S; Rubbini G; Vellosillo P; Zapata-Cobo P; Velasco M; Palomino LM; Clemente S; Segarra O; Moreno-Álvarez A; Fernández-Lorenzo A; Pérez-Moneo B; Montraveta M; Sánchez C; Tolín M; Loverdos I; Fobelo MJ; Navas-López VM; Magallares L; García-Romero R; Torres-Peral R; Rodríguez A; Bossacoma F; Merino-Bohórquez V; Salcedo E; Álvarez R; Dopazo A; Sanjurjo-Sáez M; López-Fernández LA
Biomed Pharmacother; 2024 Apr; 173():116299. PubMed ID: 38401525
[TBL] [Abstract][Full Text] [Related]
5. Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD.
Gaujoux R; Starosvetsky E; Maimon N; Vallania F; Bar-Yoseph H; Pressman S; Weisshof R; Goren I; Rabinowitz K; Waterman M; Yanai H; Dotan I; Sabo E; Chowers Y; Khatri P; Shen-Orr SS;
Gut; 2019 Apr; 68(4):604-614. PubMed ID: 29618496
[TBL] [Abstract][Full Text] [Related]
6. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease.
Verstockt B; Verstockt S; Dehairs J; Ballet V; Blevi H; Wollants WJ; Breynaert C; Van Assche G; Vermeire S; Ferrante M
EBioMedicine; 2019 Feb; 40():733-742. PubMed ID: 30685385
[TBL] [Abstract][Full Text] [Related]
7. Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.
Faleck DM; Shmidt E; Huang R; Katta LG; Narula N; Pinotti R; Suarez-Farinas M; Colombel JF
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):238-245.e4. PubMed ID: 32569749
[TBL] [Abstract][Full Text] [Related]
8. Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies.
Bar-Yoseph H; Pressman S; Blatt A; Gerassy Vainberg S; Maimon N; Starosvetsky E; Ungar B; Ben-Horin S; Shen-Orr SS; Chowers Y;
Gastroenterology; 2019 Nov; 157(5):1338-1351.e8. PubMed ID: 31401142
[TBL] [Abstract][Full Text] [Related]
9. Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis.
Hedin CRH; Sado G; Ndegwa N; Lytvyak E; Mason A; Montano-Loza A; Gerussi A; Saffioti F; Thorburn D; Nilsson E; Larsson G; Moum BA; van Munster KN; Ponsioen CY; Levy C; Nogueira NF; Bowlus CL; Gotlieb N; Shibolet O; Lynch KD; Chapman RW; Rupp C; Vesterhus M; Jørgensen KK; Rorsman F; Schramm C; Sabino J; Vermeire S; Zago A; Cazzagon N; Marschall HU; Ytting H; Ben Belkacem K; Chazouilleres O; Almer S; ; Bergquist A
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2295-2304.e2. PubMed ID: 32068151
[TBL] [Abstract][Full Text] [Related]
10. Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab.
Jessen B; Rodriguez-Sillke Y; Sonnenberg E; Schumann M; Kruglov A; Freise I; Schmidt F; Maul J; Kühl AA; Glauben R; Lissner D; Siegmund B
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):721-731.e1. PubMed ID: 32272247
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
12. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.
Miler M; Nikolac Gabaj N; Ćelap I; Grazio S; Tomašić V; Bišćanin A; Mitrović J; Đerek L; Morović-Vergles J; Vrkić N; Štefanović M
Rheumatol Int; 2021 Dec; 41(12):2195-2203. PubMed ID: 34623480
[TBL] [Abstract][Full Text] [Related]
13. Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients.
de Jong ME; Smits LJT; van Ruijven B; den Broeder N; Russel MGVM; Römkens TEH; West RL; Jansen JM; Hoentjen F
J Crohns Colitis; 2020 Jul; 14(7):888-895. PubMed ID: 31974546
[TBL] [Abstract][Full Text] [Related]
14. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists.
Guo A; Ross C; Chande N; Gregor J; Ponich T; Khanna R; Sey M; Beaton M; Yan B; Kim RB; Wilson A
Sci Rep; 2022 Jan; 12(1):1185. PubMed ID: 35075155
[TBL] [Abstract][Full Text] [Related]
15. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease.
Lee JWJ; Plichta D; Hogstrom L; Borren NZ; Lau H; Gregory SM; Tan W; Khalili H; Clish C; Vlamakis H; Xavier RJ; Ananthakrishnan AN
Cell Host Microbe; 2021 Aug; 29(8):1294-1304.e4. PubMed ID: 34297922
[TBL] [Abstract][Full Text] [Related]
16. Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease.
Salvador-Martín S; Bossacoma F; Pujol-Muncunill G; Navas-López VM; Gallego-Fernández C; Viada J; Muñoz-Codoceo R; Magallares L; Martínez-Ojinaga E; Moreno-Álvarez A; Solar-Boga A; Segarra O; Clemente S; Rodriguez-Martinez A; Alvarez-Vayo C; Loverdos I; Merino-Bohórquez V; Balboa-Vega MJ; Blanca-García JA; Fobelo MJ; Millán-Jiménez A; García-Romero R; Sanchez C; Tolín M; Caldas RG; Eizaguirre FJ; Sánchez-Hernandez JG; Torres-Peral R; Aznal E; García-González X; Sanjurjo-Sáez M; López-Fernández LA
J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):508-515. PubMed ID: 32773718
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment.
Di Sabatino A; Santilli F; Guerci M; Simeone P; Ardizzone S; Massari A; Giuffrida P; Tripaldi R; Malara A; Liani R; Gurini E; Aronico N; Balduini A; Corazza GR; Davì G
Thromb Haemost; 2016 Aug; 116(3):486-95. PubMed ID: 27305860
[TBL] [Abstract][Full Text] [Related]
18. No effect of anti-TNF-α agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: a prospective multi-center pilot study.
El-Hussuna A; Qvist N; Zangenberg MS; Langkilde A; Siersma V; Hjort S; Gögenur I
BMC Surg; 2018 Nov; 18(1):91. PubMed ID: 30390672
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin D is Upregulated by Synergy of Notch Signalling and TNF-α in the Inflamed Intestinal Epithelia of IBD Patients.
Kawamoto A; Nagata S; Anzai S; Takahashi J; Kawai M; Hama M; Nogawa D; Yamamoto K; Kuno R; Suzuki K; Shimizu H; Hiraguri Y; Yui S; Oshima S; Tsuchiya K; Nakamura T; Ohtsuka K; Kitagawa M; Okamoto R; Watanabe M
J Crohns Colitis; 2019 Mar; 13(4):495-509. PubMed ID: 30395194
[TBL] [Abstract][Full Text] [Related]
20. An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease.
Brubaker DK; Kumar MP; Chiswick EL; Gregg C; Starchenko A; Vega PN; Southard-Smith AN; Simmons AJ; Scoville EA; Coburn LA; Wilson KT; Lau KS; Lauffenburger DA
Sci Signal; 2020 Aug; 13(643):. PubMed ID: 32753478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
